---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-026187"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:26:37.035320+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allurion relaunches balloon in France after ANSM clearance; exploring combo GLP-1 trial

## Summary
- ANSM cleared Allurion to resume sales of Allurion Balloon in France, effective immediately (Feb 13, 2025).
- France historically represented approximately 15% of Allurion's revenue.
- Company plans clinical trial combining balloon with GLP-1s to study prevention of muscle loss during GLP-1 therapy.
- Previous study: patients with balloon gained 5.6% lean body mass while losing 14% total weight over 4 months.
- Another study: 167 patients lost 15.7% weight with no change in muscle mass.

## SEC filing metadata
- accession: 0001193125-25-026187
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000119312525026187/0001193125-25-026187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000119312525026187/d826753d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-026187
- JSON: https://secwatch.observer/filing/0001193125-25-026187.json
- Plain text: https://secwatch.observer/filing/0001193125-25-026187.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.